Novel approaches and current challenges with targeting the endocannabinoid system.
Novel approaches and current challenges with targeting the endocannabinoid system.
复制标题
DOI:
10.1080/17460441.2020.1752178
复制
发表时间:
2020-08
影响因子:
6.3
通讯作者:
Jagerovic N
中科院分区:
文献类型:
--
作者:
Morales P;Jagerovic N
The pathophysiological relevance of the endocannabinoid system has been widely demonstrated in a variety of diseases including cancer, neurological disorders and metabolic issues. Therefore, targeting the receptors and the endogenous machinery involved in this system can provide a successful therapeutic outcome. Ligands targeting the canonical cannabinoid receptors, CB1 and CB2, along with inhibitors of the endocannabinoid enzymes have been thoroughly studied in diverse disease models. In fact, phytocannabinoids such as cannabidiol or Δ9-tetrahydrocannabinol are currently on the market for the management of neuropathic pain due to spasticity in multiple sclerosis, or seizures in children epilepsy amongst others. Challenges in the pharmacology of cannabinoids arise from its pharmacokinetics, off-target effects and psychoactive effects. In this context, the current review outlines the novel molecular approaches emerging in the field discussing their clinical potential. Even if orthosteric CB1 and CB2 ligands are on the forefront in cannabinoid clinical research, emerging strategies such as allosteric or biased modulation of these receptors along with controlled off-targets effects may increase the therapeutic potential of cannabinoids.
登录
查看更多内容
影响因子:
4
作者:
Djeungoue-Petga, Marie-Ange;Hebert-Chatelain, Etienne
通讯作者:
Hebert-Chatelain, Etienne
影响因子:
3.8
作者:
Atsmon, Jacob;Cherniakov, Irina;Sacks, Hagit
通讯作者:
Sacks, Hagit
影响因子:
4.7
作者:
Celorrio, Marta;Rojo-Bustamante, Estefania;Aymerich, Maria S.
通讯作者:
Aymerich, Maria S.
影响因子:
3.7
作者:
Chung, Hery;Fierro, Angelica;Pessoa-Mahana, C. David
通讯作者:
Pessoa-Mahana, C. David
影响因子:
12.6
作者:
Aguareles, Jose;Paraiso-Luna, Juan;Galve-Roperh, Ismael
通讯作者:
Galve-Roperh, Ismael